Cargando…

Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review

BACKGROUND: Cancer and its therapies increase the risk of venous thromboembolism. Compared to patients without cancer, patients with cancer anticoagulated for venous thromboembolism are more likely to develop recurrent thrombotic events and major bleeding. Addressing all important outcomes including...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akl, Elie A, Barba, Maddalena, Rohilla, Sandeep, Terrenato, Irene, Sperati, Francesca, Muti, Paola, Schünemann, Holger J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2507703/ https://www.ncbi.nlm.nih.gov/pubmed/18634550 http://dx.doi.org/10.1186/1756-9966-27-21

Ejemplares similares

An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation
por: Schünemann, Holger J, et al.
Publicado: (2010)

Assessing and presenting summaries of evidence in Cochrane Reviews
por: Langendam, Miranda W, et al.
Publicado: (2013)

Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review
por: Akl, Elie A, et al.
Publicado: (2008)

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
por: Bamber, Luke, et al.
Publicado: (2015)

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
por: Lanitis, Tereza, et al.
Publicado: (2017)

Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism
por: Chen, Dong-Yi, et al.
Publicado: (2021)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline
por: Al-Hameed, Fahad, et al.
Publicado: (2015)

The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in long-distance travelers
por: Al-Hameed, Fahad M., et al.
Publicado: (2017)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in medical and critically ill patients
por: Al-Hameed, Fahad M., et al.
Publicado: (2016)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism
por: Smythe, Maureen A., et al.
Publicado: (2016)

Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis
por: Barba, Maddalena, et al.
Publicado: (2009)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism: Outpatient versus inpatient management
por: Al-Hameed, Fahad M., et al.
Publicado: (2015)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
por: Sun, Ke-Xin, et al.
Publicado: (2021)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2021)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
por: Spyropoulos, Alex C, et al.
Publicado: (2008)

Spontaneous Heparin-Induced Thrombocytopenia and Venous Thromboembolism following Total Knee Arthroplasty
por: Baker, Kevin, et al.
Publicado: (2017)

Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
por: Mearns, Elizabeth S, et al.
Publicado: (2014)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism
por: Adediran, Samuel, et al.
Publicado: (2017)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
por: Liu, Zhi-Yan, et al.
Publicado: (2022)

Educational games in geriatric medicine education: a systematic review
por: Alfarah, Ziad, et al.
Publicado: (2010)

Diagnostic Accuracy of Contrast-Enhanced, Spectral Mammography (CESM) and 3T Magnetic Resonance Compared to Full-Field Digital Mammography plus Ultrasound in Breast Lesions: Results of a (Pilot) Open-Label, Single-Centre Prospective Study
por: Ferranti, Francesca Romana, et al.
Publicado: (2022)

Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis
por: Lopes, Luciane Cruz, et al.
Publicado: (2014)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
por: Smrke, Alannah, et al.
Publicado: (2017)

Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
por: Yoon, Dongwon, et al.
Publicado: (2023)

Interpreting the results of patient reported outcome measures in clinical trials: The clinician's perspective
por: Schünemann, Holger J, et al.
Publicado: (2006)

Cost-effectiveness of diagnostic strategies for venous thromboembolism: a systematic review
por: Zhang, Yuan, et al.
Publicado: (2022)

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
por: Prandoni, Paolo
Publicado: (2008)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8vdtrd4krarjbn0enhlfu3fupm